Mechanisms of disease: Antiphospholipid antibodies - From clinical association to pathologic mechanism

Nature Clinical Practice Rheumatology

Volumn 4, Issue 4, 2008, Pages 192-199

  de Laat, Bas ^a   Mertens, Koen ^b   de Groot, Philip G ^c  

^a SANQUIN RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; CONFORMATIONAL TRANSITION; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS WASTAGE; HIGH RISK PATIENT; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; BLOOD; DRUG RESISTANCE; HISTORY; IMMUNOLOGY; METABOLISM;

ANNEXIN A5; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; DRUG RESISTANCE; HISTORY, 20TH CENTURY; HUMANS; LUPUS COAGULATION INHIBITOR; THROMBOSIS;

EID: 45549086562     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0740     Document Type: Review

References (47)

1. Levine JS et al. (2002) The antiphospholipid syndrome. N Engl J Med 346: 752-763
2. Galli M et al. (2003) Anti-β2-glycoprotein I and antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 102: 2717-2723
3. Galli M et al. (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 101: 1827-1832
4. Wasserman A et al. (1906) Eine serodiagnostiche reaction bei syphilis [German]. Dtsch Med Wochenschr 32: 745
5. Pangborn MC (1941) A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med 48: 484-486
6. Moore JE and Mohr GF (1952) Biologically false positive tests for syphilis: Type, incidence, and cause. J Am Med Association 150 467-473
7. Moore JE and Lutz WB (1955) Natural history of systemic lupus erythematosus: Approach to its study through chromic biological false positive reactors. J Chronic Dis 1: 297-316
8. Conley CL and Hartman RCA (1952) A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 31: 621-622
9. Beaumont JL (1954) Syndrome hemorrhagic acquis du a un anticoagulant [French]. Sang 25: 1-5
10. Bowie EJW et al. (1963) Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 62: 416-430
11. Galli M et al. (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335 1544-1547
12. Matsuura H et al. (1990) Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336: 117-118
13. McNeil HD et al. (1990) Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87: 4120-4124
14. Bevers EM et al. (1991) Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66: 629-632
15. De Laat B et al. (2004) β2-glycoprotein I, playmaker in the antiphospholipid syndrome. Clin Immunol 112: 161-168
16. Wilson WA et al. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 42: 1309-1311
17. Miyakis S et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295-306
18. Consigny PH et al. (2002) High prevalence of co-factor independent anticardiolipin antibodies in malaria exposed individuals. Clin Exp Immunol 127: 158-164
19. Abuaf N et al. (1997) Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb Haemost 77: 856-861
20. Uhtman IW et al. (2002) Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 31: 256-263
21. De Laat B et al. (2005) IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood 105: 1540-1545
22. Opatrny L et al. (2006) Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 33: 2214-2221
23. De Laat HB et al. (2004) β2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104: 3598-3602
24. Pengo V et al. (2005) Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 93: 1147-1152
25. Devreese KM (2007) A functional coagulation test to identify anti-β2-glycoprotein I dependent lupus anticoagulants. Thromb Res 119: 753-759
26. Pengo V (2004) A two-step coagulation test to identify antiβ-glycoprotein I lupus anticoagulants. J Thromb Haemost 2 702-707
27. Cervera R et al. (2002) Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46: 1019-1027
28. Yang CD et al. (1998) Detection of anti-recombinant β2-glycoprotein I fifth-domain antibodies in sera from patients with systemic lupus erythematosus. Rheumatol Int 18: 5-10
29. Igarashi M et al. (1996) Human β2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 87: 3262-3270
30. George J et al. (1998) Target recognition of β2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: Evidence for involvement of the fourth domain of β2GPI in antibody binding. J Immunol 160: 3917-3923
31. McNeely PA et al. (2001) β2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I. Thromb Haemost 86: 590-595
32. Reddel SW et al. (2000) Epitope studies with anti-β2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 15: 91-96
33. Iverson GM et al. (1998) Anti-β2-glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI. Proc Natl Acad Sci USA 95: 15542-15546
34. Iverson GM et al. (2002) Use of single point mutations in domain I of β2GPI to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 169: 7097-7103
35. Blank M et al. (1999) Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 96: 5164-5168
36. Giannakopoulos B et al. (2007) Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109: 422-430
37. Rand JH et al. (1997) Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 337: 154-160
38. Rand JH et al. (2004) Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 104: 2783-2790
39. De Laat B et al. (2007) Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 109: 1490-1494
40. Gardiner C et al. (2006) Detection of acquired resistance to activated protein C associated with anti phospholipid antibodies using a novel clotting assay. Blood Coagul Fibrinolysis 17: 477-483
41. Nojima J et al. (2005) Acquired activated protein C resistance associated with IgG antibodies against β2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 51: 545-552
42. De Laat B et al. (2007) Correlation between the potency of a β2-glycoprotein I dependent lupus anticoagulant and the level of resistance to activated protein C [abstract]. Abstract P-S-539, XXIst congress of the ISTH, Geneva
43. van Lummel M et al. (2005) The binding site in β2-glycoprotein I for ApoER2' on platelets is located in domain V. J Biol Chem 280: 36729-36736
44. Pennings MT et al. (2007) Platelets express three different splice variants of ApoER2 that are all involved in signalling. J Thromb Haemost 5: 1538-1544
45. Urbanus RT et al. (2007) Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. Blood Rev [doi:1 0. 1016/j.bire.2007.09.001]
46. Hulstein JJ et al. (2007) β2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 110: 1483-1491
47. Pittoni V and Valesini G (2002) The clearance of apoptotic cells: implications for autoimmunity. Autoimmun Rev 1: 154-161